Document:

<PAGE>
                                                                    EXHIBIT 10.2

                                   AMENDMENT

                                     TO THE

                          DATATRAK INTERNATIONAL, INC.

             AMENDED AND RESTATED 1994 DIRECTORS' SHARE OPTION PLAN

         This Amendment (the "Amendment") to the DATATRAK International, Inc.
Amended and Restated 1994 Directors' Share Option Plan is made this 18th day of
December, 2001 by DATATRAK International, Inc. (the "Company").

                               W I T N E S S E T H

         WHEREAS, the Company's Board of Directors adopted the Company's Amended
and Restated 1994 Directors' Share Option Plan (the "Plan") on July 16, 1994;
and

         WHEREAS, the Plan was approved by action of the Company's shareholders
on July 16, 1994; and

         WHEREAS, the Company, as a condition to the consummation of a private
placement of the Company's common shares and pursuant to the terms of a Share
Purchase Agreement among the Company and the investors parties thereto, has
agreed to amend each of its stock option plans to place certain restrictions on
the granting of stock options; and

         WHEREAS, the Board of Directors has deemed it necessary and appropriate
to adopt such amendments to each of the Company's stock option plans to place
certain restrictions on the granting of stock options.

         NOW, THEREFORE, in consideration of the foregoing, the Plan is amended
as follows:

         CERTAIN RESTRICTIONS. The following language shall be added to the Plan
as a new section:

                  "Notwithstanding anything in the foregoing to the contrary,
         the Company shall not, unless approved by the holders of a majority of
         the shares present and entitled to vote at a duly convened meeting of
         shareholders:

         (i)      grant any stock option, including stock appreciation right,
                  with an exercise price that is less than 100% of the fair
                  market value of the underlying stock on the date of grant; or

                                       1
<PAGE>

         (ii)     reduce the exercise price of any stock option, including stock
                  appreciation right, outstanding or to be granted in the
                  future; cancel and re-grant options at a lower exercise price
                  (including entering into any "6 month and 1 day" cancellation
                  and re-grant program), whether or not the canceled options are
                  put back into the available pool for grant; replace
                  out-of-the-money options with restricted stock in an exchange,
                  buy-back or other program; or replace any options with new
                  options having a lower exercise price or accelerated vesting
                  schedule in an exchange, buy-back or other program.

         The prohibitions set forth in items (i) and (ii) above may not be
         further amended or repealed without the affirmative vote of the holders
         of a majority of the shares present and entitled to vote at a duly
         convened meeting of shareholders."

         IN WITNESS WHEREOF, DATATRAK International, Inc., by its appropriate
officers duly authorized, has executed this Amendment as of the 18th day of
December, 2001.

                               DATATRAK INTERNATIONAL, INC.

                               By:      /S/ JEFFREY A. GREEN
                                  --------------------------------------
                               Jeffrey A. Green, President and Chief Executive
                                  Officer

                               By:      /S/ TERRY C. BLACK
                                  --------------------------------------
                               Terry C. Black, Vice President of Finance, Chief
                                  Financial Officer, Treasurer and Assistant
                                  Secretary

                                       2<PAGE>
                                                                    EXHIBIT 10.4

                                 AMENDMENT NO. 1

                                     TO THE

                      COLLABORATIVE CLINICAL RESEARCH, INC.
          AMENDED AND RESTATED 1996 OUTSIDE DIRECTORS STOCK OPTION PLAN

         This Amendment No. 2 (the "Amendment") to the Collaborative Clinical
Research, Inc. Amended and Restated 1996 Outside Directors Stock Option Plan is
made this 20th day of May, 1997 by Collaborative Clinical Research, Inc. (the
"Company").

                               W I T N E S S E T H

         WHEREAS, on September 20, 1996, the Company's shareholders approved and
adopted the Collaborative Clinical Research, Inc. Amended and Restated 1996
Outside Directors Stock Option Plan (the "Plan"); and

         WHEREAS, at a meeting held on September 17, 1998, the Company's Board
of Directors deemed it necessary to amend certain provisions of the Plan in
order to (i) increase the number of Common Shares subject to the Plan, (ii)
modify the formula for automatic option grants, (iii) modify the vesting period
of options granted and (iv) require the execution of written agreements for each
option grant.

         NOW, THEREFORE, in consideration of the foregoing, the Plan is amended
as follows:

         1. COMMON SHARES SUBJECT TO THE PLAN. The second paragraph of Section 3
of the Plan is deleted in its entirety and the following paragraph is
substituted in lieu thereof:

         "Subject to the provisions of the next succeeding paragraph of this
Section 3, the aggregate number of Common Shares for which options may be
granted under the Plan shall be Fifty Thousand (50,000) Common Shares."

         IN WITNESS WHEREOF, Collaborative Clinical Research, Inc., by its
appropriate officers duly authorized, has executed this Amendment No. 1 as of
the 20th day of May, 1997.

                                          COLLABORATIVE CLINICAL RESEARCH, INC.

                                          By:
                                            /s/ JEFFREY A. GREEN
                                            ------------------------------------
                                            Jeffrey A. Green, Pharm.D., FCP,
                                            President and Chief Executive
                                              Officer

                                          By:
                                            /s/ TERRY C. BLACK
                                            ------------------------------------
                                            Terry C. Black
                                            Vice President of Finance and Chief
                                             Financial Officer<PAGE>

                                                                    EXHIBIT 10.5

                                 AMENDMENT NO. 2

                                     TO THE

                      COLLABORATIVE CLINICAL RESEARCH, INC.
          AMENDED AND RESTATED 1996 OUTSIDE DIRECTORS STOCK OPTION PLAN

         This Amendment No. 2 (the "Amendment") to the Collaborative Clinical
Research, Inc. Amended and Restated 1996 Outside Directors Stock Option Plan is
made this 17th day of September, 1998 by Collaborative Clinical Research, Inc.
(the "Company").

                               W I T N E S S E T H

         WHEREAS, on September 20, 1996, the Company's shareholders approved and
adopted the Collaborative Clinical Research, Inc. Amended and Restated 1996
Outside Directors Stock Option Plan, as amended on May 20, 1997 (the "Plan");
and

         WHEREAS, at a meeting held on September 17, 1998, the Company's Board
of Directors deemed it necessary to amend certain provisions of the Plan in
order to (i) increase the number of Common Shares subject to the Plan, (ii)
modify the formula for automatic option grants, (iii) modify the vesting period
of options granted and (iv) require the execution of written agreements for each
option grant.

         NOW, THEREFORE, in consideration of the foregoing, the Plan is amended
as follows:

         1. COMMON SHARES SUBJECT TO THE PLAN. Subject to shareholder approval,
the second paragraph of Section 3 of the Plan is deleted in its entirety and the
following paragraph is substituted in lieu thereof:

         "Subject to the provisions of the next succeeding paragraph of this
Section 3, the aggregate number of Common Shares for which options may be
granted under the Plan shall be One Hundred Seventy-five Thousand (175,000)
Common Shares."

         2. GRANT OF OPTIONS.

         (a) AUTOMATIC GRANTS. Section 4(a) of the Plan is deleted in its
entirety and the following paragraph is substituted in lieu
thereof:

         "Subject to the terms of the Plan (including without limitation the
receipt of shareholder approval contemplated by Section 2 hereof), each eligible
Director shall be granted a non-qualified stock option to purchase such number
of Common Shares as follows:

               (i) Each Director who was an eligible Director on July 23, 1998
shall receive a non-qualified stock option to purchase Ten Thousand (10,000)
Common Shares, and the price at which such Common Shares may be purchased shall
be equal to the "fair market value" of such shares as of July 23, 1998; and

               (ii) Each eligible Director newly appointed or elected, or
re-elected, to the Board of Directors after July 23, 1998 shall thereupon be
granted a non-qualified stock option to purchase Ten Thousand (10,000) Common
Shares; and

               (iii) On the first business day immediately following the date of
each of the Company's regular meetings of shareholders at which Directors are
elected, commencing with the meeting to be held in 1999, each eligible Director
shall be granted a non-qualified stock option to purchase Two Thousand Five
Hundred (2,500) Common Shares.

                                       1
<PAGE>

          Subject to the terms of the Plan, all such grants shall occur
automatically without any further action by the Board of Directors. Each grant
of options awarded hereunder shall also be subject to the terms and provisions
of a written agreement as provided by Section 4(e) hereof."

         3. VESTING OF OPTIONS. Section 4(d) of the Plan is deleted in its
entirety and the following paragraph is substituted in lieu thereof:

         "Each eligible Director shall be entitled to exercise options granted
under the Plan as follows:

               (i) With respect to options granted pursuant to paragraphs (i) or
(ii) of Section 4(a) above, each such option shall become fully vested and
exercisable as to 3,333 of the underlying Common Shares on the day following the
first anniversary of the Date of Grant, 6,666 of the underlying Common Shares on
the day following the second anniversary of the Date of Grant and 10,000 of the
underlying Common Shares on the third anniversary of the Date of Grant; and

               (ii) With respect to options granted pursuant to paragraph (iii)
of Section 4(a) above, each such option shall become fully vested and
exercisable as to all of the underlying Common Shares on the day following the
first anniversary of the Date of Grant."

         4. WRITTEN AGREEMENT. The following Section 4(e) is inserted beneath
Section 4(d) of the Plan as follows:

               "e. WRITTEN AGREEMENT. Upon each grant of an option under the
Plan, each eligible Director shall enter into a written agreement with the
Company, a form of which is attached hereto as Exhibit A. The execution of such
written agreement shall be a condition to the receipt of such option."

         IN WITNESS WHEREOF, Collaborative Clinical Research, Inc., by its
appropriate officers duly authorized, has executed this Amendment No. 2 as of
the 17th day of September, 1998.

                                          COLLABORATIVE CLINICAL RESEARCH, INC.

                                          By:
                                            /s/ JEFFREY A. GREEN
                                            ------------------------------------
                                            Jeffrey A. Green, Pharm.D., FCP,
                                            President and Chief Executive
                                              Officer

                                          By:
                                            /s/ TERRY C. BLACK
                                            ------------------------------------
                                            Terry C. Black
                                            Vice President of Finance and Chief
                                              Financial Officer

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]